Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. The company develops Bucillamine-based therapies, psilocybin-based therapeutics, and Long COVID diagnostics, as well as commercializes delivery technologies for psychedelics and cannabinoids. Revive Therapeutics Ltd. was founded in 2012 and is based in Toronto, Canada.…
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Revive Therapeutics (CNSX: RVV) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.0100 CAD on 20 November 2026, down 33.3% over 52 weeks. Its 52-week range is 0.0050 CAD to 0.0800 CAD: the price is 87.5% below the high and 100.0% above the low.
Its market capitalisation is 4.45M CAD.
Revive Therapeutics reports return on equity of 318.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.83K CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.